Groups representing 340B covered entities are emphasizing the positives in what they say was a federal judge’s otherwise disappointing opinion Wednesday on whether drug makers must offer 340B ceiling prices when covered entities use contract pharmacies.
The groups’ message is, the government lives on to fight another day, and so do we.
Groups representing 340B covered entities are emphasizing the positives in what they say was a federal judge’s otherwise disappointing opinion Wednesday on whether drug makers must offer 340B ceiling prices when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, take advantage of our lowest-ever discount opportunity which we have extended through June 21: 25% off our regular subscription rates. Subscribe now using coupon code INVESTIGATE25 at checkout.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
